此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估 Fenebrutinib 与 Teriflunomide 治疗复发性多发性硬化症 (RMS) 疗效和安全性的研究 (FENhance)

2026年9月16日 更新者:Hoffmann-La Roche

一项 III 期多中心随机、双盲、双模拟、平行组研究,以评估 Fenebrutinib 与 Teriflunomide 在复发性多发性硬化症成人患者中的疗效和安全性

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.

研究概览

研究类型

介入性

注册 (实际的)

746

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国
        • Beijing Tiantan Hospital,Capital Medical University
      • Beijing、中国、100034
        • Peking University First Hospital
      • Changchun、中国、130021
        • the First Hospital of Jilin University
      • Changsha、中国、410008
        • Xiangya Hospital Central South University
      • Chengdu、中国、610041
        • West China Hospital, Sichuan University
      • Chongqing、中国、400016
        • The First Affiliated Hospital, Chongqing Medical University
      • Guangzhou、中国、510080
        • The First Affiliated Hospital of Sun Yat-sen University
      • Guangzhou、中国、510260
        • The second Affiliated Hospital of Guangzhou Medical University
      • Guiyang、中国
        • The affiliated Hospital of Guiyang Medical College
      • Kunming、中国、650021
        • The First People?s Hospital of Yunnan Province
      • Shijiazhuang、中国、05000
        • The Second Hospital of Hebei Medical University
      • Suzhou、中国、215031
        • The First Affiliated Hospital of Soochow University
      • Taiyuan、中国
        • 1st Affiliated Hospital of Shanxi Medical University
      • Tianjin、中国、300052
        • Tianjin Medical University General Hospital
      • Wuhan、中国、430030
        • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
      • Xi'an、中国
        • Tangdu Hospital, The Fourth Military Medical University
      • Ürümqi、中国、830000
        • Xinjiang People Hospital
      • Dnipro、乌克兰、49027
        • SI USSRI of Medical and Social Problems of Disabilities of MOHU
      • Kharkiv、乌克兰、61068
        • Ams of Ukraine
      • Kyiv、乌克兰、03037
        • Medical Center of Private Execution First Private Clinic
      • Kyiv、乌克兰、02123
        • Medical Center Dopomoga Plus
      • Lviv、乌克兰、79010
        • Lviv Regional Clinical Hospital
      • Lviv、乌克兰、79029
        • "Neurofocus" LLC
      • Odesa、乌克兰、65117
        • Odesa Regional Clinical Hospital
      • Vinnytsi、乌克兰、21009
        • Medical Clinical Research Center of Medical Center LLC Health Clinic
      • Zaporizhzhya、乌克兰、69600
        • Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council
      • Zaporizhzhya、乌克兰、69035
        • LCC "Medical center "Unimed"
    • KIEV Governorate
      • Vinnytsia、KIEV Governorate、乌克兰、21009
        • Salutem Medical Center
    • Tavria Okruha
      • Dnipro、Tavria Okruha、乌克兰
        • Separated structural unit ?University hospital? of Dnipro State Medical University
      • Tbilisi、乔治亚州、0179
        • Khechinashvili University Hospital
      • Tbilisi、乔治亚州、0114
        • New Hospitals
      • Tbilisi、乔治亚州、0114
        • Pineo Medical Ecosystem
      • Tbilisi、乔治亚州、0160
        • MediClab Georgia
      • Tbilisi、乔治亚州、0159
        • St. Michael hospital
      • Kirov、俄罗斯、610007
        • Center of Cardiology and Neurology
      • Novosibirsk、俄罗斯、630007
        • FSBIH Siberian Regional Medical Centre of FMBA of Russia
    • Bashkortostan Republic
      • Ufa、Bashkortostan Republic、俄罗斯、450005
        • Republican clinical hospital named after G.G. Kuvatov
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、197022
        • Pavlov State Medical Uni
    • Ulyanovsk Oblast
      • Ulyanovsk、Ulyanovsk Oblast、俄罗斯、432063
        • Ulyanovsk Regional Clinical Hospital
      • Budapest、匈牙利、1033
        • Clinexpert Kft.
      • Budapest、匈牙利、1044
        • S-Medicon Egeszsegugyi Szolgaltato Kft.
      • Eger、匈牙利、3300
        • Markhot Ferenc Oktatokorhaz és Rendelointezet
      • Kistarcsa、匈牙利、2143
        • Pest Megyei Flor Ferenc Korhaz
      • Szeged、匈牙利、6725
        • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
      • Shtip、北马其顿、2000
        • Clinical Hospital Stip
      • Skopje、北马其顿、1000
        • PHO General City Hospital 8th September Center for dialysis
      • Skopje、北马其顿、1000
        • University Clinic for Neurology - Skopje
      • Belgrade、塞尔维亚、11000
        • University Clinical Center of Serbia
    • Coahuila
      • Saltillo、Coahuila、墨西哥、25050
        • Clinical Research Institute Saltillo
    • Mexico CITY (federal District)
      • Mexico City、Mexico CITY (federal District)、墨西哥、03100
        • Grupo Medico de Investigacion Clinica Multidisciplinaria
      • Mexico City、Mexico CITY (federal District)、墨西哥、03100
        • Health Pharma Professional Research
    • Sinaloa
      • Culiacán、Sinaloa、墨西哥、80020
        • Neurociencias Estudios Clinicos S.C.
    • Tlaxcala
      • Mexico、Tlaxcala、墨西哥、06726
        • Hospital General de Mexico
      • Santiago de los Caballeros、多明尼加共和国、51000
        • NeuroINC
      • Santo Domingo、多明尼加共和国、10210
        • Hospital Padre Billini
      • Berlin、德国、13347
        • Jüdisches Krankenhaus Berlin
      • Böblingen、德国、71034
        • Studienzentrum Dr. Bischof GmbH
      • Dresden、德国、01307
        • Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
      • Giessen、德国、35385
        • Universitätsklinikum Gießen und Marburg GmbH
      • Kiel、德国、24105
        • Uniklinik Schleswig-Holstein
      • Stuttgart、德国、70174
        • Praxis Dr. med. Andreas Kowalik, Arzt für Neurologie und Psychiatrie
      • Tübingen、德国、72076
        • Universitätsklinikum Tübingen, Zentrum für Neurologie
      • Ulm、德国、89081
        • Universitätsklinikum Ulm
      • Westerstede、德国、26655
        • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
    • Apulia
      • Foggia、Apulia、意大利、71100
        • AO.U. Policlinico Riuniti Foggia
    • Campania
      • Naples、Campania、意大利、80131
        • AOU Seconda Università degli Studi
      • Naples、Campania、意大利、80138
        • AOU Policlinico - Università L. Vanvitelli
    • Emilia-Romagna
      • Parma、Emilia-Romagna、意大利、43126
        • A.O.U. di Parma
    • Lazio
      • Rome、Lazio、意大利、00185
        • Policlinico Umberto I
      • Rome、Lazio、意大利、00189
        • Azienda Ospedaliera Sant'Andrea
      • Rome、Lazio、意大利、00133
        • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    • Lombardy
      • Bergamo、Lombardy、意大利、24127
        • ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
      • Milan、Lombardy、意大利、20132
        • IRCCS Ospedale San Raffaele
    • Piedmont
      • Mondovì (CN)、Piedmont、意大利、12084
        • Ospedale Regina Montis Regalis
    • Sicily
      • Catania、Sicily、意大利、95123
        • AOU Policlinico V. Emanuele - P.O G. Rodolico
    • Veneto
      • Padova、Veneto、意大利、35128
        • Azienda Ospedaliera di Padova
      • ?ory、波兰、44-240
        • ProNeuro Centrum Medyczne
      • Bydgoszcz、波兰、85-796
        • Neurocentrum Bydgoszcz sp. z o.o
      • Katowice、波兰、40-568
        • Care Clinic
      • Krosno、波兰、38-400
        • MT Medic Krosno
      • Lodz、波兰、90-324
        • Centrum Neurologii Krzysztof Selmaj
      • Lublin、波兰、20-492
        • Rodzinne Centrum Medyczne Lubimed.pl
      • Warsaw、波兰、02-957
        • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
      • Zabrze、波兰、41-800
        • IBISMED Wielospecjalistyczne Centrum Medyczne
      • Bern、瑞士、3010
        • Inselspital Bern Medizin Neurologie
      • Lugano、瑞士、6903
        • Ospedale Regionale di Lugano - Civico
      • Bellavista、秘鲁、Callao 2
        • Hospital IV Alberto Sabogal Sologuren
      • La Victoria, Lima、秘鲁、Lima 13
        • Hospital Nacional Guillermo Almenara Irigoyen
      • Lima、秘鲁、Lima 29
        • Hospital Maria Auxiliadora
      • Lima、秘鲁、15018
        • Hospital Nacional Dos de Mayo
      • Lima、秘鲁、Lima 01
        • Clinica Internacional Sede Lima
      • Pueblo Libre、秘鲁、Lima 21
        • Clinica Centenario Peruano Japonesa
      • Mannouba、突尼斯、2010
        • Hopital Razi
      • Monastir、突尼斯、5000
        • Fattouma Bourguiba Hospital
      • Sfax、突尼斯、3029
        • Hospital Habib Bourguiba
    • Alabama
      • Birmingham、Alabama、美国、35233
        • University of Alabama Birmingham
      • Homewood、Alabama、美国、35209
        • Alabama Neurology Associates
    • Arizona
      • Phoenix、Arizona、美国、85032
        • Center for Neurology and Spine - Phoenix - Hunt - PPDS
    • California
      • Carlsbad、California、美国、92011
        • Profound Research, LLC
      • Irvine、California、美国、92697
        • University of California Irvine
      • Pasadena、California、美国、91106
        • Quantum Clinical Research, Inc
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Denver
      • Denver、Colorado、美国、80209
        • Mountain View Clinical Research
      • Fort Collins、Colorado、美国、80528
        • Advanced Neurology of Colorado, LLC
    • Florida
      • Maitland、Florida、美国、32751
        • Neurology Associates, PA; Research Department
    • Illinois
      • Highland Park、Illinois、美国、60035
        • NorthShore University HealthSystem
    • Indiana
      • Fort Wayne、Indiana、美国、46805
        • Fort Wayne Neurological Center
    • Louisiana
      • Baton Rouge、Louisiana、美国、70810
        • The NeuroMedical Center
      • Shreveport、Louisiana、美国、71103
        • Ochsner LSU Health
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins University School Of Medicine; Outpatient Center
    • Massachusetts
      • Worcester、Massachusetts、美国、01655
        • University of Massachusetts Medical School
    • Michigan
      • Detroit、Michigan、美国、48202
        • Henry Ford Health System
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • New Jersey
      • Teaneck、New Jersey、美国、07666
        • Holy Name Hospital; Institute For Clinical Research
    • New Mexico
      • Albuquerque、New Mexico、美国、87131
        • University of New Mexico; MS Specialty Clinic
    • Ohio
      • Centerville、Ohio、美国、45459
        • Miami Valley Hospital South; Dayton Physician's Office
      • Columbus、Ohio、美国、43214
        • OhioHealth
      • Columbus、Ohio、美国、43235
        • The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • Oklahoma Medical Research Foundation; MS Center of Excellence
    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18015
        • St. Luke's University Health network
    • South Carolina
      • Greenville、South Carolina、美国、29605
        • Premier Neurology
    • Tennessee
      • Knoxville、Tennessee、美国、37920
        • New Orleans Center for Clinical Research
    • Texas
      • Plano、Texas、美国、75024
        • North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
      • Sherman、Texas、美国、75092
        • Texas Institute for Neurological Disorders
    • Virginia
      • Vienna、Virginia、美国、22182
        • Multiple Sclerosis Center of Greater Washington
    • Washington
      • Kirkland、Washington、美国、98034
        • Evergreen MS Center
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53215
        • Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
      • Nairobi、肯尼亚、00100
        • The Aga Khan University-Kenya.
      • Helsinki、芬兰、00290
        • Helsinki University Central Hospital
      • Sittard-Geleen、荷兰、6162 BG
        • Zuyderland Medisch Centrum - Sittard Geleen
      • Braga、葡萄牙、4710-243
        • Hospital de Braga
      • Coimbra、葡萄牙、3000-075
        • HUC
      • Lisbon、葡萄牙、1500-650
        • Hospital da Luz
      • Lisbon、葡萄牙、1169-050
        • Hospital Santo Antonio dos Capuchos
      • Porto、葡萄牙、4200-319
        • Hospital de Sao Joao
      • Porto、葡萄牙、4099-001
        • Hospital Geral de Santo Antonio
      • Santa Maria da Feira、葡萄牙、4520-211
        • Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião
      • Barcelona、西班牙、08035
        • Hospital Universitari Vall d'Hebron
      • Madrid、西班牙、28034
        • Hospital Ramon y Cajal
      • Madrid、西班牙、28007
        • Hospital General Universitario Gregorio Marañon
      • Madrid、西班牙、28040
        • Fundacion Jimenez Diaz
      • Madrid、西班牙、28006
        • Hospital Universitario de la Princesa
      • Málaga、西班牙、29010
        • Hospital Regional Universitario de Malaga ? Hospital General
      • Seville、西班牙、41009
        • Hospital Universitario Virgen Macarena
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、西班牙、08907
        • Hospital Universitari de Bellvitge
    • Madrid
      • Pozuelo de Alarcón、Madrid、西班牙、28223
        • Hospital Quiron de Madrid
    • Murcia
      • EL Palmar (EL Palmar)、Murcia、西班牙、30120
        • Hospital Universitario Virgen de Arrixaca
    • Pontevedra
      • Vigo、Pontevedra、西班牙、36213
        • Hospital Alvaro Cunqueiro
      • Buenos Aires、阿根廷、C1424
        • Centro de Especialidades Neurológicas y Rehabilitación - CENyR
      • Buenos Aires、阿根廷、C1405BCH
        • IME - Instituto Médico Especializado
      • Buenos Aires、阿根廷、C1182ACA
        • Neurologia Infantil Buenos Aires (NIBA)
      • C. A. B. A.、阿根廷、C1055AAF
        • CIER
      • Rosario、阿根廷、2000
        • Diagnostico Medico Oroño
      • San Juan、阿根廷、J5400CEP
        • Cer San Juan
      • San Miguel de Tucumán、阿根廷、T4000AXL
        • Centro de Investigaciones Médicas Tucuman
      • Hong Kong、香港
        • Pamela Youde Nethersole Eastern Hospital
      • Shatin, New Territories、香港
        • Prince of Wales Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening
  • A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
  • Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in < 240 seconds
  • Ability to perform the Timed 25-Foot Walk Test (T25FWT) in < 150 seconds
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm

OLE Inclusion Criteria:

  • Completed the DBT phase of the study (remaining on study treatment; no other disease-modifying therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
  • Participants randomized to the teriflunomide treatment arm during the DBT phase must undergo the accelerated teriflunomide elimination procedure (ATEP) prior to the first administration of open-label fenebrutinib
  • For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating eggs
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and refrain from donating sperm

Exclusion Criteria:

  • Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0
  • Female participants who are pregnant or breastfeeding, or intending to become pregnant
  • Male participants who intend to father a child during the study
  • A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
  • Any known or suspected active infection at screening, including but not limited to a positive screening test for hepatitis B (HBV) and hepatitis C (HCV), an active or latent or inadequately treated infection with tuberculosis (TB), a confirmed or suspected progressive multifocal leukoencephalopathy (PML)
  • History of cancer including hematologic malignancy and solid tumors within 10 years of screening
  • Known presence of other neurological disorders, that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study and clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal (GI) disease
  • Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
  • Hypoproteinemia
  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months
  • Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert's Syndrome
  • Participants with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
  • History of alcohol or other drug abuse within 12 months prior to screening
  • History of or currently active primary or secondary (non-drug-related) immunodeficiency, including known history of human immunodeficiency virus (HIV) infection
  • Inability to complete an MRI scan
  • Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to screening (inhaled and topical corticosteroids are allowed)
  • Receipt of a live-attenuated vaccine within 6 weeks prior to randomization
  • Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period

OLE Exclusion Criteria:

  • Acute liver disease
  • Chronic liver disease unless considered stable for > 6 months
  • Cirrhosis (Child-Pugh Class A, B, or C)
  • Gilbert's syndrome

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Fenebrutinib

Participants will receive oral (PO) fenebrutinib, with teriflunomide-matching placebo.

Participants will receive fenebrutinib.

Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.

有源比较器:Teriflunomide

Participants will receive PO teriflunomide, with fenebrutinib-matching placebo in a blinded fashion.

Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.

Participants will receive teriflunomide.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
年化复发率 (ARR)
大体时间:至少96周
至少96周

次要结果测量

结果测量
大体时间
复合 12 周确认残疾进展的开始时间 (cCDP12)
大体时间:至少96周
至少96周
复合 24 周确认残疾进展的开始时间 (cCDP24)
大体时间:至少96周
至少96周
12 周确认残疾进展的开始时间 (CDP12)
大体时间:至少96周
至少96周
24 周确认残疾进展的开始时间 (CDP24)
大体时间:至少96周
至少96周
Fenebrutinib 在指定时间点的血浆浓度
大体时间:长达 4.5 年
长达 4.5 年
复合材料12周的发作时间与复发活性无关(CPIRA12)
大体时间:至少96周
至少96周
参与者发生不良事件(AEs)的百分比
大体时间:最长4.5年
最长4.5年
Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI)
大体时间:Baseline, Weeks 12, 24, 48 and 96
Baseline, Weeks 12, 24, 48 and 96
Percentage Change in Total Brain Volume From Week 24 as Assessed by MRI
大体时间:From Week 24 to Week 96
From Week 24 to Week 96
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score
大体时间:Minimum of 96 weeks
Minimum of 96 weeks
Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), as Measured by the Multiple Sclerosis Impact Scale (29-item), Version 2 (MSIS-29) Physical Scale
大体时间:Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96
Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light Chain (NfL)
大体时间:Baseline, Week 48
Baseline, Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trials、Hoffmann-La Roche

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年3月17日

初级完成 (实际的)

2026年1月27日

研究完成 (估计的)

2027年11月30日

研究注册日期

首次提交

2020年10月8日

首先提交符合 QC 标准的

2020年10月8日

首次发布 (实际的)

2020年10月14日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • GN41851
  • 2019-004857-10 (EudraCT编号)
  • 2019 (美国 NIH 拨款/合同)
  • 2022-502609-14-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅